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Abstract
Background: General supportive and preventive measures in the intensive care management of traumatic brain injury
(TBI) aim to prevent or limit secondary brain injury and optimize recovery. The aim of this survey was to assess and quantify
variation in perceptions on intensive care unit (ICU) management of patients with TBI in European neurotrauma centers.
Methods:We performed a survey as part of the Collaborative European NeuroTrauma Effectiveness Research in Traumatic
Brain Injury (CENTER-TBI) study. We analyzed 23 questions focused on: 1) circulatory and respiratory management; 2) fever
control; 3) use of corticosteroids; 4) nutrition and glucose management; and 5) seizure prophylaxis and treatment.
Results: The survey was completed predominantly by intensivists (n= 33, 50%) and neurosurgeons (n= 23, 35%) from 66
centers (97% response rate).
The most common cerebral perfusion pressure (CPP) target was > 60 mmHg (n= 39, 60%) and/or an individualized target
(n = 25, 38%). To support CPP, crystalloid fluid loading (n = 60, 91%) was generally preferred over albumin (n = 15, 23%),
and vasopressors (n = 63, 96%) over inotropes (n= 29, 44%). The most commonly reported target of partial pressure of
carbon dioxide in arterial blood (PaCO2) was 36–40 mmHg (4.8–5.3 kPa) in case of controlled intracranial pressure (ICP)
< 20 mmHg (n = 45, 69%) and PaCO2 target of 30–35 mmHg (4–4.7 kPa) in case of raised ICP (n = 40, 62%). Almost all
respondents indicated to generally treat fever (n = 65, 98%) with paracetamol (n = 61, 92%) and/or external cooling
(n = 49, 74%). Conventional glucose management (n = 43, 66%) was preferred over tight glycemic control (n = 18,
28%). More than half of the respondents indicated to aim for full caloric replacement within 7 days (n = 43, 66%)
using enteral nutrition (n = 60, 92%). Indications for and duration of seizure prophylaxis varied, and levetiracetam was
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mostly reported as the agent of choice for both seizure prophylaxis (n = 32, 49%) and treatment (n = 40, 61%).
Conclusions: Practice preferences vary substantially regarding general supportive and preventive measures in TBI
patients at ICUs of European neurotrauma centers. These results provide an opportunity for future comparative
effectiveness research, since a more evidence-based uniformity in good practices in general ICU management could
have a major impact on TBI outcome.
Keywords: Intensive care unit, Traumatic brain injury, Glucose, Nutrition, Fever, Ventilation, Blood pressure, Seizure,
Survey, Europe
Background
Traumatic brain injury (TBI) is one of the major causes of
trauma-related death and hospital admissions in Europe [1].
TBI is recognized as a complex heterogeneous syndrome
[2]. The higher vulnerability of this population is reflected
by higher mortality rates in patients with TBI compared
with non-head injured trauma patients [3]. Therefore, pa-
tients with (severe) TBI require specialized neurointensive
care (treatment) at an intensive care unit (ICU) [4].
Case fatality rates in severe TBI are high, ranging from
30% to 40% in unselected observational series [5]. Fur-
thermore, substantial between-country [1] and between-
center differences [3, 4, 6] in overall TBI mortality rates
exist which might be partly explained by differences in
treatment [7–9].
The key objectives of ICU TBI management are to
maintain general physiology and prevent secondary brain
injury. A number of brain-specific therapies, such as intra-
cranial pressure (ICP)-guided treatment or, less often,
brain-metabolic or cerebral vascular autoregulation-based
goals are employed both clinically or as the subject of clin-
ical research [10]. However, general support of the cardio-
vascular system, respiratory function, and nutritional or
metabolic needs must not be overlooked and could also
have a significant impact on outcome [11, 12]. Cerebral
metabolic control by seizure or fever management may
further contribute to better outcomes [2, 13–15]. At
present, optimal strategies for general management are
only partly established [16, 17]. This lack of robust evi-
dence may ultimately result in institutional or individual
variations in practice that may contribute to variances in
outcome.
The aim of this survey study was to assess variation in
ICU management perceptions of general supportive and
preventive care policies (including, for instance, circula-
tory and respiratory management) in patients with TBI
in European neurotrauma centers.
Methods
Participating centers
This study is part of the Collaborative European Neuro-
Trauma Effectiveness Research in Traumatic Brain In-
jury (CENTER-TBI) study that collects data on patient
characteristics, patient management, and outcomes in 68
centers from 20 countries across Europe and Israel [18].
All these centers were asked to complete a ‘Provider
Profiling Questionnaire’ [19]. The questionnaire items
used for this study (treatment at the intensive care) are
attached as Additional file 1.
Provider profiling questionnaire
The provider profiling questionnaire was developed in
several stages. First, literature was explored for evidence,
including guidelines and available surveys. Second, a
pilot study was conducted in 16 participating centers to
receive feedback, to determine ambiguity, and to detect
unexpected and missing values. Throughout all stages,
experts of various disciplines (neurosurgeons, intensi-
vists, neurologists, emergency department physicians, re-
habilitation physicians, medical ethicists, health care
economists, and epidemiologists) were asked for their
advice on the development of the questionnaire. Details
on the development, administration, and content of the
complete provider profiling questionnaires have been
published previously [19].
General supportive and preventive management
For the purpose of the current study, we focused on 23
questions specifically aimed at general ICU policies (Add-
itional file 1). Specifically, we focused on circulatory and re-
spiratory management, fever control, use of corticosteroids,
glucose and nutrition management, and seizure prophylaxis
and treatment. Most questions were multiple-choice, ex-
cept for two questions: the aim for caloric intake in TBI pa-
tients and the use of corticosteroids for other conditions.
Overall, the general policy of a center rather than the indi-
vidual treatment preference of the respondent was the
premise for completion of the questionnaire. General policy
is defined as: ‘the way the large majority of patients (> 75%)
with a certain indication would be treated’.
Statistical analysis
We used descriptive statistics (frequencies and percent-
ages) to present the data. Respondents could indicate
how frequently certain management strategies were
used (never 0–10%, rarely 10–30%, sometimes 30–70%,
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frequently 70–90%, and always 90–100%). The com-
bined numbers of respondents that indicated ‘fre-
quently’ and ‘always’ were interpreted as representing
the general policy of a center, in line with previous re-
ports [20, 21]. To describe center characteristics in
more detail we divided centers into higher (Austria,
Belgium, Denmark, Finland, France, Germany, Israel,
Italy, the Netherlands, Norway, Spain, Sweden, UK, and
Switzerland) versus relatively lower income countries
(Bosnia Herzegovina, Hungary, Latvia, Lithuania,
Romania, and Serbia), based on a 2007 report by the
European Commission [22]. Differences were assessed
for statistical significance using the Fisher’s exact test
without correction for multiple comparisons. We used
Statistical Package for Social Sciences (SPSS) version 21
[23] for descriptive analyses.
Results
Participating centers
Of the 68 neurotrauma centers participating in this
study, 66 (97%) centers completed the questions on gen-
eral supportive and preventive ICU management. The
questionnaire was predominantly completed by intensi-
vists (n = 33, 50%) and neurosurgeons (n = 23, 35%).
Other professionals that assisted in completion of the
questionnaire were administrative staff (n = 11, 17%),
neurologists (n = 5, 8%), anesthesiologists (n = 5, 8%),
and a trauma surgeon (n = 1, 2%).
The majority of centers had an academic affiliation
(n = 60, 91%). The majority of centers were designated
as level I trauma centers (n = 45, 69%), and a minority
as level II (n = 4, 6%), level III (n = 1, 2%), or no des-
ignation (n = 15, 23%). More than half of the centers
had a dedicated neuroICU (defined as an ICU that is
equipped to treat patients with neurological or neuro-
surgical injury) available (n = 39, 59%). The majority
of centers adopted a ‘closed’ ICU organization (the
intensivist is primarily responsible for the delivery of
care for patients at the ICU) (n = 43, 65%), followed
by a ‘mixed’ ICU organization (the admitting phys-
ician, e.g., neurosurgeon, is primarily responsible but
the care is provided by a intensivist) (n = 20, 30%),
and a minority adopted an ‘open’ ICU organization
(the admitting physician is primarily responsible for
care at the ICU) (n = 3, 5%). Centers indicated to
treat a median of 92 (interquartile range 52–160) pa-
tients with TBI at their ICU annually. Twenty-eight
centers (42%) reported to adhere to the 2007 Brain
Trauma Foundation (BTF) guidelines for the manage-
ment of patients with TBI at their ICU, and 21 cen-
ters (32%) reported having institutional guidelines that
were based on BTF guidelines. The center characteris-
tics and definitions are described in more detail in a
previous publication [19].
Circulatory and respiratory management
As part of circulatory management, the most frequently
mentioned cerebral perfusion pressure (CPP) targets
were > 60 mmHg (n = 39, 60%) and/or “individualized”
(n = 25, 38%). Most centers used crystalloids (n = 60,
91%) and/or vasopressors (n = 63, 96%) for CPP support;
inotropes (n = 29, 44%) were less frequently, but still
regularly, employed. Fifteen centers (23%) reported to
use albumin-containing solutions for volume expansion
(Additional file 2: Table S1).
In mechanically ventilated patients with TBI, initial
partial pressure of oxygen in arterial blood (PaO2)
goals of > 75 mmHg (10 kPa) (n = 29, 45%) and > 97.5
mmHg (13 kPa) (n = 29, 45%) were most commonly
cited as a treatment preference, with an initial arterial
oxygen saturation goal of > 95% (n = 56, 86%). In the
absence of raised ICP, most centers indicated a partial
pressure of carbon dioxide in arterial blood (PaCO2)
goal of 36–40 mmHg (4.8–5.3 kPa) (n = 45, 69%). In
the presence of raised ICP this shifted towards a lower
PaCO2 goal of 30–35 mmHg (4.0–4.7 kPa) (n = 40,
62%) (Fig. 1). The timing of tracheostomy in patients
with limited or slow neurological recovery varied sub-
stantially from within 1 week (n = 13, 20%) to between
1 and 2 weeks (n = 36, 55%) and more than 2 weeks
(n = 16, 25%) (Additional file 2: Table S1).
Relatively lower income countries more frequently
adopted lower oxygen saturation goals (> 90%) compared
with saturation targets > 95% which were favored by
higher income countries (n = 3/11, 27%, versus n = 2/55,
4%; p = 0.037) (Additional file 3: Table S6).
Fever control
In patients with TBI, the majority of centers indicated
that they routinely treat fever (n = 65, 98%). One center
(2%) reported they would only treat fever “sometimes”.
The preferred treatments were paracetamol (n = 61,
92%) and/or external cooling (n = 49, 74%). In contrast,
nonsteroidal anti-inflammatory drugs (NSAIDs) were
less commonly used (n = 29, 44%). Intravascular cooling
was also rarely used (n = 3, 5%) (Fig. 2) (Additional file 2:
Table S2).
Relatively lower income countries significantly
indicated the use of NSAIDs more often than higher
income countries (n = 11/11, 100%, versus n = 18/55,
33%; p = 0.000). Centers in higher income countries
indicated the use of paracetamol significantly more
frequently compared with relatively lower income
countries (n = 53/55, 96%, versus n = 8/11, 73%; p =
0.029). Intravascular cooling was more frequently
applied in the lower income group, although this
difference did not reach statistical significance
(Additional file 3: Table S7).
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Fig. 2 Type of fever treatment and corresponding percentage of centers that indicated they use this type of fever treatment never (in 0–10% of
cases), rarely (in 10–30% of cases), sometimes (in 30–70% of cases), frequently (in 70–90% of cases), or always (in 90–100% of cases). NSAID
nonsteroidal anti-inflammatory drug
Fig. 1 Mechanical ventilation thresholds with corresponding answer frequencies; 25–29 mmHg ≈ 3.3–3.0 kPa, 30–35 mmHg ≈ 4–4.7 kPa, 36–40
mmHg ≈ 4.8–5.3 kPa, 41–45 mmHg ≈ 5.5–6 kPa, 60 mmHg = 8 kPa, 75 mmHg = 10 kPa, 100 mmHg = 13 kPa. * No specific goal (n = 1), > 90
mmHg (n = 2); ^ > 96% (n = 2), > 97% (n = 1), 92–94% (n = 1). PaCO2 partial pressure of carbon dioxide in arterial blood, PaO2 partial pressure of
oxygen in arterial blood
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Use of corticosteroids
Corticosteroids were infrequently used for the primary
management of brain injury, although a few respondents
indicated that they used them “rarely” (n = 5, 8%), “some-
times” (n = 2, 3%), or “frequently” (n = 1, 2%). However,
corticosteroids were specifically used for vasopressor-
resistant hypotension (n = 21, 58%) and, to a lesser extent,
sepsis (n = 8, 22%) (Additional file 2: Table S3).
Primary use of corticosteroids was significantly more
frequently reported by lower income countries com-
pared with higher income countries (n = 4/11, 36%, ver-
sus n = 4/55, 7%; p = 0.023) (Additional file 3: Table S7).
Glucose and nutrition management
The majority of centers stated that their glucose man-
agement was protocolized (n = 50, 77%). Most centers
reported the correction of hyperglycemia as a primary
aim (n = 43, 66%) while a smaller number implemented
tight glycemic control (n = 18, 28%) (Additional file 2:
Table S4).
Most respondents aimed for full caloric replacement
within 7 days post-injury (n = 43, 66%). An open ques-
tion on the goals for caloric intake showed a high variety
in reported strategies as well as metrics used (kcal/day,
kcal/kg/day, and percentages). The enteral route was
preferred (n = 60, 92%). The timing of parenteral nutri-
tion was highly variable: centers were equally distributed
between “as soon as possible” (n = 13, 20%), “within 24 h
post-injury” (n = 13, 20%), “within 72 h post-injury” (n =
10, 15%), “within 7 days post-injury” (n = 17, 26%), and
“we do not have rules/guidelines for this” (n = 12, 19%)
(Additional file 2: Table S4).
Relatively lower income countries reported using the
parenteral route significantly more frequently compared
with higher income countries (n = 4/11, 36%, versus n =
1/55, 2%, p = 0.002) (Additional file 3: Table S7).
Seizure prophylaxis and treatment
There was little consensus regarding the use of prophy-
lactic antiepileptic drugs (for all indications). Most cen-
ters reported to use levetiracetam as the drug of choice
for both seizure prophylaxis and treatment (n = 32, 49%,
and n = 40, 61%), followed by phenytoin (n = 20, 31%,
and n = 32, 48%) (Fig. 3). In general, both the reported
duration of antiseizure prophylaxis and the criteria for
initiation of antiepileptic treatment varied considerably
(Additional file 2: Table S5).
The choice of agent varied with income, with levetirac-
etam being less commonly used for both seizure prophy-
laxis (n = 0/11 versus n = 32/55, 59%; p = 0.000) and
treatment (n = 1/11, 9%, versus n = 39/55, 71%; p =
0.000) in the lower income group versus higher income
countries, respectively. Instead, lower income countries
seemed to favor valproate or phenytoin compared with
higher income countries (n = 7/11, 64%, versus n = 14/
55, 26%; p = 0.029) (Additional file 3: Table S7).
Discussion
In this survey, we found varying degrees of consensus
between European neurotrauma centers with respect to
general supportive and preventive ICU management in
patients with TBI. Most variation was found in initial
PaO2 goals for mechanically ventilated patients, CPP
Fig. 3 Agents for seizure prophylaxis and treatment with corresponding percentage of centers that indicated that they never (in 0–10% of cases),
rarely (in 10–30% of cases), sometimes (in 30–70% of cases), frequently (in 70–90% of cases), or always (in 90–100% of cases) use the agent.
*Carbamazepine/phenobarbital, phenobarbital, benzodiazepines, no prophylaxis used in our hospital, carbamazepine (n = 3). ^Phenobarbital,
benzodiazepines, carbamazepine (n = 4), midazolam/diazepam, lorazepam
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targets, the timing of tracheostomy in unconscious patients,
nutritional targets, and seizure prophylaxis and treatment.
Large between-center variation was found in topics
that are not addressed in the recommendations of the
BTF guidelines (Additional file 4), suggesting the role
of guidelines in reducing variances in clinical practice.
International guidelines (BTF guidelines and guidelines
of the American College of Surgeons) do recommend
the use of normalized thresholds (e.g., normoglycemia,
normocapnia, and normothermia) in patients with TBI,
although this is not based on high-level evidence [16, 17].
Indeed, randomized controlled trials (RCTs) on these
topics are too limited in number to lead to high-level evi-
dence [10]. Considering CPP targets, the BTF guidelines
are unclear whether to use an optimum threshold of > 60
or > 70 mmHg (and a range of 50–70 mmHg in the pre-
vious BTF guidelines [24]). Despite this ambiguity, a
majority of respondents (60%) preferred a target CPP of >
60 mmHg. In addition, the current BTF guidelines added
that the CPP target might depend on the individual ce-
rebral autoregulatory status, reflected by 38% of respon-
dents who indicated to use an individualized target CPP.
The uniformity in reported CPP targets between income
groups also suggests that these concepts are widespread.
It may be that the willingness to individualize CPP in
patients with TBI reflects the growing trend for use of pre-
cision medicine [25], where therapies and therapy targets
are individualized to patient need, rather than used on a
“one size fits all” basis.
Marked variation was also found on topics where con-
sensus was expected based on high-level evidence from
RCTs or the recommendations in the BTF guidelines.
The use of steroids for the primary management of TBI
was reported by 13% of the respondents (one respondent
reported frequent use), but is against the advice of the
BTF guidelines and contradicts the prevailing evidence
from the CRASH study [26, 27]. However, use in the
majority of centers was for vasopressor dependence and/
or sepsis, a use in keeping with current guidelines for
the management of sepsis [28]. The use of albumin was
reported by 23% of the respondents, while the SAFE
study showed that albumin was associated with higher
mortality rates in patients with TBI [29]. It is difficult to
interpret the continued use of albumin for volume ex-
pansion as a lack of knowledge of the evidence, since
worse outcomes in the albumin-treated arm in SAFE-
TBI may have been the consequence of a hypotonic car-
rier causing elevated ICP [30], and well-informed clini-
cians may have used albumin that was isotonic or
corrected any accompanying hyponatremia. Finally, the
use of tight glycemic control was reported by 28% of re-
spondents, while the NICE-SUGAR and CGAO-REA
studies recommend using moderate instead of tight glu-
cose control in patients with TBI [31, 32].
On the other hand, we found consensus where vari-
ation was expected; a high number of centers indicated
they use antipyretic agents for the treatment of fever
when there is no consensus on the optimal choice of
agent and when their potentially deleterious side-effect
of CPP lowering is well known [33]. This suggests a
strong aversion amongst treating clinicians to allow pyr-
exia in patients with TBI. The choice of NSAIDs, despite
their well-known potentially harmful systemic side-effect
profile, as antipyretics in many centers probably also re-
flects this, although a continuous intravenous infusion
instead of intermittent NSAID dosing might improve
fever control (with relatively higher CPP) in neurocritical
care [34]. In addition, respondents indicated employing
below-normal PaCO2 goals (30–35 mmHg) in the pres-
ence of raised ICP in mechanically ventilated TBI patients.
This was unexpected given the BTF recommendation to
avoid prolonged hyperventilation. Furthermore, even pa-
tients in whom intracranial hypertension was not a con-
cern were ventilated to normal carbon dioxide tensions
showing a reluctance to use permissive ventilatory strat-
egies that have been shown to be effective in reducing
mortality in acute respiratory distress syndrome (ARDS)
patients [35].
Our results further suggest that respondents use TBI-
specific strategies instead of general strategies (as used
in the general critically ill patients) in the ICU. For ex-
ample, respondents indicated they frequently or always
treat fever since hyperthermia is associated with worse
outcomes in TBI [14, 33], whereas fever is often consid-
ered beneficial to some extent in critically ill patients
with infections [36].
We found some differences between relatively lower
versus higher income countries. It was striking that leve-
tiracetam was significantly more frequently reported by
higher income countries as an agent of choice for seiz-
ure prophylaxis and treatment, while valproate and
phenytoin were reported more frequently by lower in-
come countries, although high-level evidence in the lit-
erature on the agent of choice is lacking [37]. However,
there were no clear structural differences in manage-
ment overall, and this could not therefore be considered
an explanation for the treatment variation. Indeed, some
high-cost interventions, such as intravascular cooling
and parenteral nutrition, were more commonly used in
the lower income countries, suggesting that choices of
treatment options are not solely based on cost consider-
ations, but also reflect local clinical culture in different
institutions.
Our study has several strengths. To our knowledge,
this is the first survey that provides an overview of mul-
tiple components of general supportive or preventive
ICU management in patients with TBI. The survey was
developed in several stages with involvement of clinical
Huijben et al. Critical Care  (2018) 22:90 Page 6 of 9
experts of various disciplines and the response rate of
the survey was high (97%). However, this study also has
limitations, as the centers participating in the CENTER-
TBI study may still be a biased selection of European
centers with a specialist interest in the topic, or a large
engagement in research, or more expertise overall. In a
small number of centers, the questionnaire was com-
pleted by administrative staff (with no clinical expertise).
However, presumably this was in close collaboration
with a clinician considering the high number of clini-
cians that completed the survey, and clinical involve-
ment was encouraged throughout the survey. Other
limitations are inherent to surveys in that the results are
self-reported and are not confirmed by independent ob-
servations in daily practice and, therefore, represent
what the respondents ‘believe’ is clinical practice and
this may not, in fact, reflect reality. Another limitation is
that the survey questions represent generalizations and
do not include patient factors (such as demographics, la-
boratory results, or imaging), or very specific circum-
stances, while in clinical practice these details influence
clinicians’ judgement. In line with this, we did not spe-
cify time frames (for ventilation goals) and laboratory
values (for tight glucose control). Also, we asked about
general patients with TBI in the survey and did not spe-
cify adult or pediatric TBI.
Overall, the practice variation (and consensus) in gen-
eral ICU management we found might be explained by a
lack of evidence (or incomplete implementation of evi-
dence), by the use of individualized approaches, or by a
tension between general and TBI-specific strategies. We
presume that increased and more evidence-based uni-
formity in good practices in general ICU management
might improve outcome in TBI. In fact, general ICU
management is part of daily routine (e.g., temperature
measurements, laboratory results, and mechanical venti-
lation) and deviations are generally easily detected and
corrected. It is noteworthy that non-neurological com-
plications are frequent; in one report on TBI patients
these were more frequent (around 22%) than neuro-
logical complications (around 3%) [29]. Our survey
showed that future research on individualized manage-
ment is needed; a high number of respondents reported
individualized practices which implies a trend towards
precision medicine. In addition, the existence of practice
variation in general ICU management provides direction
to comparative effectiveness research (CER) analyses or
RCTs. As RCTs in the field of TBI have been disappoint-
ing [10], CER might be a promising approach to enhance
future knowledge on the effectiveness of general ICU
management, and understanding what process variances
occur, as we have attempted to do, is a critical starting
point. Hence, in the CENTER-TBI study we will evaluate
the effect of different ICU management practices on TBI
outcome (after case-mix correction); for example, the
difference in patient outcome between the 13 centers
that plan tracheostomy within 1 week, the 36 centers
that time tracheostomy between 1 and 2 weeks, and the
16 centers that delay tracheostomy longer than 2 weeks.
Conclusions
This study shows that general supportive and preventive
ICU management policies in TBI vary between European
neurotrauma centers. These findings stress the need for
continued knowledge transfer of existing evidence, fur-
ther research on optimized individualized management
(precision medicine) and, as we propose, comparative
effectiveness research.
Additional files
Additional file 1: Survey questions: survey questions of the ‘Provider
Profiling Questionnaire’ used in the study (treatment in the intensive care
unit). (DOCX 23 kb)
Additional file 2: Overview of all results: circulatory and respiratory
management (Table S1), fever control (Table S2), use of corticosteroids
(Table S3), glucose and nutrition management (Table S4), seizure
prophylaxis and treatment (Table S5). (DOCX 26 kb)
Additional file 3: Variation between higher and lower income countries:
variation in thresholds used for circulatory and respiratory management
(Table S6) and general treatments in the ICU (Table S7). (DOCX 22 kb)
Additional file 4: Comparison with the Brain Trauma foundation
recommendations: items of the questionnaire with corresponding
recommendations in the Brain Trauma Foundation guidelines for the
Management of Severe Traumatic Brain Injury (4th edition). (DOCX 17 kb)
Additional file 5: CENTER-TBI investigators and participants participating
in the CENTER-TBI study and their corresponding affiliations. (DOCX 33 kb)
Abbreviations
BTF: Brain trauma foundation; CENTER-TBI: Collaborative european
neurotrauma effectiveness research in traumatic brain injury;
CER: Comparative effectiveness research; CPP: Cerebral perfusion pressure;
ICP: Intracranial pressure; ICU: Intensive care unit; NSAID: Nonsteroidal anti-
inflammatory drug; PaCO2: Partial pressure of carbon dioxide in arterial
blood; PaO2: Partial pressure of oxygen in arterial blood; RCT: Randomized
controlled trial; TBI: Traumatic brain injury
Acknowledgements
The authors would like to thank all clinical and research staff at the CENTER-TBI
sites for completing the provider profiling questionnaires. The CENTER-TBI
investigators and participants are listed in Additional file 5.
Funding
European Commission FP7 Framework Program 602150. Data used in the
preparation of this manuscript were obtained in the context of CENTER-TBI, a
large collaborative project with the support of the European Commission
7th Framework program (602150). The funder had no role in the design of
the study, the collection, analysis, and interpretation of data, or in writing the
manuscript.
Availability of data and materials
There are legal constraints that prohibit us from making the data publicly
available. Since there are only a limited number of centers per country
included in this study (for two countries only one center), data will be
identifiable. Readers may contact Dr. Hester F. Lingsma (h.lingsma@erasmusmc.nl)
for reasonable requests for the data.
Huijben et al. Critical Care  (2018) 22:90 Page 7 of 9
Authors’ contributions
JAH analyzed the data and drafted the manuscript, the supplementary tables
and the figures. VV and MvdJ gave feedback on the manuscript and MvdJ
supervised the project. All coauthors were involved in the design of the
survey and the distribution of the survey. All coauthors gave feedback on
(and approved) the final version of the manuscript.
Ethics approval and consent to participate
Not applicable since no patients participated, and the centers have given
consent by completing the questionnaire.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Center for Medical Decision Making, Department of Public Health, Erasmus
Medical Center Rotterdam, Rotterdam, the Netherlands. 2Department of
Neurosurgery, Office H-703, Erasmus MC Stroke Center and Brain Tumor
Center, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands.
3Department of Pathophysiology and Transplants, University of Milan, Milan,
Italy. 4Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico,
Department of Anesthesia and Critical Care, Neuroscience Intensive Care
Unit, Milan, Italy. 5Department of Neurosurgery, Antwerp University Hospital
and University of Antwerp, Edegem, Belgium. 6Division of Anaesthesia,
University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK. 7School of
Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
8Neurointensive Care, San Gerardo Hospital, ASST-Monza, Monza, Italy.
9Section for Perioperative Medicine and Intensive Care, Department of
Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
10Department of Medical Statistics and Bioinformatics, Leiden University
Medical Center, Leiden, the Netherlands. 11Department of Intensive Care and
Erasmus MC Stroke Center, Erasmus Medical Center, Rotterdam, the
Netherlands.
Received: 31 October 2017 Accepted: 19 February 2018
References
1. Majdan MDP. Epidemiology of traumatic brain injuries in Europe: a cross-
sectional analysis. Lancet Public Health. 2016;1:e76–83.
2. Stocchetti N, Carbonara M, Citerio G, Ercole A, Skrifvars MB, Smielewski P,
Zoerle T, Menon DK. Severe traumatic brain injury: targeted management in
the intensive care unit. Lancet Neurol. 2017;16(6):452–64.
3. Patel HC, Bouamra O, Woodford M, King AT, Yates DW, Lecky FE, Trauma
A, Research N. Trends in head injury outcome from 1989 to 2003 and the
effect of neurosurgical care: an observational study. Lancet. 2005;
366(9496):1538–44.
4. Moore L, Evans D, Hameed SM, Yanchar NL, Stelfox HT, Simons R, Kortbeek
J, Bourgeois G, Clement J, Lauzier F, et al. Mortality in Canadian trauma
systems: a multicenter cohort study. Ann Surg. 2017;265(1):212–7.
5. Rosenfeld JV, Maas AI, Bragge P, Morganti-Kossmann MC, Manley GT, Gruen
RL. Early management of severe traumatic brain injury. Lancet. 2012;
380(9847):1088–98.
6. Lingsma HF, Roozenbeek B, Li B, Lu J, Weir J, Butcher I, Marmarou A, Murray
GD, Maas AI, Steyerberg EW. Large between-center differences in outcome
after moderate and severe traumatic brain injury in the international
mission on prognosis and clinical trial design in traumatic brain injury
(IMPACT) study. Neurosurgery. 2011;68(3):601–7. discussion 607–8
7. Cnossen MC, Polinder S, Andriessen TM, van der Naalt J, Haitsma I, Horn J,
Franschman G, Vos PE, Steyerberg EW, Lingsma H. Causes and consequences
of treatment variation in moderate and severe traumatic brain injury: a
multicenter study. Crit Care Med. 2017;45(4):660–9.
8. Bulger EM, Nathens AB, Rivara FP, Moore M, MacKenzie EJ, Jurkovich GJ,
Brain TF. Management of severe head injury: institutional variations in care
and effect on outcome. Crit Care Med. 2002;30(8):1870–6.
9. Alali AS, Fowler RA, Mainprize TG, Scales DC, Kiss A, de Mestral C, Ray JG,
Nathens AB. Intracranial pressure monitoring in severe traumatic brain
injury: results from the American College of Surgeons Trauma Quality
Improvement Program. J Neurotrauma. 2013;30(20):1737–46.
10. Bragge P, Synnot A, Maas AI, Menon DK, Cooper DJ, Rosenfeld JV, Gruen RL.
A state-of-the-science overview of randomized controlled trials evaluating
acute management of moderate-to-severe traumatic brain injury. J
Neurotrauma. 2016;33(16):1461–78.
11. Mascia L, Sakr Y, Pasero D, Payen D, Reinhart K, Vincent JL, Sepsis Occurrence
in Acutely Ill Patients (SOAP) Investigators. Extracranial complications in
patients with acute brain injury: a post-hoc analysis of the SOAP study.
Intensive Care Med. 2008;34(4):720–7.
12. Costello LA, Lithander FE, Gruen RL, Williams LT. Nutrition therapy in
the optimisation of health outcomes in adult patients with moderate
to severe traumatic brain injury: findings from a scoping review. Injury.
2014;45(12):1834–41.
13. Stocchetti N, Taccone FS, Citerio G, Pepe PE, Le Roux PD, Oddo M, Polderman
KH, Stevens RD, Barsan W, Maas AI, et al. Neuroprotection in acute brain injury:
an up-to-date review. Crit Care. 2015;19:186.
14. Bonds BW, Hu P, Li Y, Yang S, Colton K, Gonchigar A, Cheriyan J, Grissom T,
Fang R, Stein DM. Predictive value of hyperthermia and intracranial
hypertension on neurological outcomes in patients with severe traumatic
brain injury. Brain Inj. 2015;29(13–14):1642–7.
15. Majidi S, Makke Y, Ewida A, Sianati B, Qureshi AI, Koubeissi MZ. Prevalence
and risk factors for early seizure in patients with traumatic brain injury:
analysis from National Trauma Data Bank. Neurocrit Care. 2017;27(1):90–5.
16. Carney N, Totten AM, O'Reilly C, Ullman JS, Hawryluk GW, Bell MJ, Bratton
SL, Chesnut R, Harris OA, Kissoon N, et al. Guidelines for the management of
severe traumatic brain injury, fourth edition. Neurosurgery. 2017;80(1):6–15.
17. American College of Surgeons, Trauma Quality Improvement Program
guideline: Best Practices in the Management of Traumatic Brain Injury.
https://www.facs.org/quality-programs/trauma/tqip/best-practice.
18. Maas AI, Menon DK, Steyerberg EW, Citerio G, Lecky F, Manley GT, Hill S,
Legrand V, Sorgner A, Participants C-T, et al. Collaborative European
NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI):
a prospective longitudinal observational study. Neurosurgery. 2015;76(1):67–80.
19. Cnossen MC, Polinder S, Lingsma HF, Maas AI, Menon D, Steyerberg EW,
CENTER-TBI Investigators and Participants. Variation in structure and process
of care in traumatic brain injury: provider profiles of European neurotrauma
centers participating in the CENTER-TBI study. PLoS One. 2016;11(8):e0161367.
20. Hesdorffer DC, Ghajar J. Marked improvement in adherence to traumatic
brain injury guidelines in United States trauma centers. J Trauma.
2007;63(4):841–7. discussion 847–8
21. Cnossen MC, Huijben JA, van der Jagt M, Volovici V, van Essen T, Polinder S,
Nelson D, Ercole A, Stocchetti N, Citerio G, et al. Variation in monitoring and
treatment policies for intracranial hypertension in traumatic brain injury: a
survey in 66 neurotrauma centers participating in the CENTER-TBI study. Crit
Care. 2017;21(1):233.
22. European Commission. Remuneration of researchers in the public and
private sectors. Brussels: European Communities; 2007.
23. Corp IBM. IBM SPSS Statistics for Windows (or Macintosh), Version 21.0.
Armonk: IBM Corp.; 2012.
24. Brain Trauma Foundation, American Association of Neurological Surgeons,
Congress of Neurological Surgeons. Guidelines for the management of
severe traumatic brain injury. J Neurotrauma. 2007;24(Suppl 1):S1–106.
25. Maas AIR, Menon DK, Adelson PD, Andelic N, Bell MJ, Belli A, Bragge P,
Brazinova A, Buki A, Chesnut RM, et al. Traumatic brain injury: integrated
approaches to improve prevention, clinical care, and research. Lancet
Neurol. 2017;16(12):987–1048.
26. Roberts I, Yates D, Sandercock P, Farrell B, Wasserberg J, Lomas G,
Cottingham R, Svoboda P, Brayley N, Mazairac G, et al. Effect of intravenous
corticosteroids on death within 14 days in 10008 adults with clinically
significant head injury (MRC CRASH trial): randomised placebo-controlled
trial. Lancet. 2004;364(9442):1321–8.
27. Edwards P, Arango M, Balica L, Cottingham R, El-Sayed H, Farrell B, Fernandes J,
Gogichaisvili T, Golden N, Hartzenberg B, et al. Final results of MRC CRASH, a
randomised placebo-controlled trial of intravenous corticosteroid in adults
with head injury-outcomes at 6 months. Lancet. 2005;365(9475):1957–9.
Huijben et al. Critical Care  (2018) 22:90 Page 8 of 9
28. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A,
Sevransky JE, Sprung CL, Nunnally ME, et al. Surviving Sepsis Campaign:
international guidelines for management of sepsis and septic shock: 2016.
Crit Care Med. 2017;45(3):486–552.
29. SAFE Study Investigators, Australian and New Zealand Intensive Care
Society Clinical Trials Group, Australian Red Cross Blood Service, George
Institute for International Health, Myburgh J, Cooper DJ, Finfer S, Bellomo R,
Norton R, et al. Saline or albumin for fluid resuscitation in patients with
traumatic brain injury. N Engl J Med. 2007;357(9):874–84.
30. Cooper DJ, Myburgh J, Heritier S, Finfer S, Bellomo R, Billot L, Murray L,
Vallance S, SAFE-TBI Investigators, Australian and New Zealand Intensive
Care Society Clinical Trials Group. Albumin resuscitation for traumatic brain
injury: is intracranial hypertension the cause of increased mortality? J
Neurotrauma. 2013;30(7):512–8.
31. NICE-SUGAR Study Investigators for the Australian and New Zealand
Intensive Care Society Clinical Trials Group and the Canadian Critical Care
Trials Group, Finfer S, Chittock D, Li Y, Foster D, Dhingra V, Bellomo R, Cook
D, et al. Intensive versus conventional glucose control in critically ill patients
with traumatic brain injury: long-term follow-up of a subgroup of patients
from the NICE-SUGAR study. Intensive Care Med. 2015;41(6):1037–47.
32. Cinotti R, Ichai C, Orban JC, Kalfon P, Feuillet F, Roquilly A, Riou B, Blanloeil
Y, Asehnoune K, Rozec B. Effects of tight computerized glucose control on
neurological outcome in severely brain injured patients: a multicenter sub-
group analysis of the randomized-controlled open-label CGAO-REA study.
Crit Care. 2014;18(5):498.
33. Stocchetti N, Rossi S, Zanier ER, Colombo A, Beretta L, Citerio G. Pyrexia in
head-injured patients admitted to intensive care. Intensive Care Med.
2002;28(11):1555–62.
34. Cormio M, Citerio G. Continuous low dose diclofenac sodium infusion to
control fever in neurosurgical critical care. Neurocrit Care. 2007;6(2):82–9.
35. Acute Respiratory Distress Syndrome Network, Brower RG, Matthay MA, Morris A,
Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as
compared with traditional tidal volumes for acute lung injury and the
acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–8.
36. Chiumello D, Gotti M, Vergani G. Paracetamol in fever in critically ill patients—an
update. J Crit Care. 2017;38:245–52.
37. Khan NR, VanLandingham MA, Fierst TM, Hymel C, Hoes K, Evans LT, Mayer
R, Barker F, Klimo P Jr. Should levetiracetam or phenytoin be used for
posttraumatic seizure prophylaxis? A systematic review of the literature and
meta-analysis. Neurosurgery. 2016;79(6):775–82.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Huijben et al. Critical Care  (2018) 22:90 Page 9 of 9
